Weiss and his group's work targets lung tissue bioengineering, that involves the usage of a scaffold – or framework – of lungs from human being cadavers to engineer new lungs for sufferers with end-stage disease. Their studies have examined multiple perspectives on the procedure of stripping the cellular materials from these lungs – known as decellularizing – and changing it with stem cells , in order to grow new, healthy lungs for transplantation. Employed in animal and human being models, Wagner, Weiss and co-workers have addressed numerous issues faced through the lung tissue bioengineering process, such as the storage and sterilization of decellularized cadaveric scaffolds and the influence of the age and disease condition of donor lungs on these procedures.Non-AJ BRCA individuals experienced a 2.15 times greater odds of complete response to initial chemotherapy response over sporadic, noncarrier individuals. Karen Lu, M.D., associate professor in the Section of Gynecologic Oncology at M. D. Anderson and senior author on the study said the difference in survival rates indicate that individuals with BRCA mutations might react better to regular chemotherapy for ovarian malignancy. Thus, it becomes more and more valuable to know a patient’s BRCA status to guide and personalize treatment decisions, Lu said.